24/7 Market News Snapshot 31 July, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)

July 31, 2025

DENVER, Colo., 31 July, 2025 (www.247marketnews.com) – (NASDAQ:PSTV) are discussed in this article.
PLUS Therapeutics, Inc. (NASDAQ:PSTV) is currently experiencing a significant uptick in market interest, with shares trading at $0.558, marking a notable increase of 22.02% from the previous close of $0.457. With an impressive trading volume of 6.24 million, the heightened activity reflects a robust investor sentiment towards the company’s prospects. This bullish momentum comes as the company advances its innovative initiatives within the biotechnology sector.

In parallel, PSTV recently announced the upcoming launch of its subsidiary, CNSide Diagnostics, LLC, which will introduce the CNSide cerebrospinal fluid (CSF) assay platform in August 2025. This cutting-edge platform is specifically designed to enhance diagnostic capabilities for patients at risk of leptomeningeal metastases (LM), a serious condition affecting a significant percentage of cancer patients. The CNSide CSF assay utilizes advanced laboratory-developed technology to detect tumor cells in cerebrospinal fluid, providing critical insights for patient management and treatment strategies.

Targeted initially at National Cancer Institute (NCI) Designated Cancer Centers, the rollout will focus on large healthcare systems that have adopted the CNSide method. Dr. Michael Youssef, an Assistant Professor in Neurology and Hematology and Oncology, highlighted the assay’s potential, stating that it offers essential guidance in monitoring disease progression and treatment options, thereby representing a considerable advancement in patient care.

With CNS metastases impacting up to 30% of adult cancer patients, timely and effective diagnostics are vital for ensuring appropriate treatment pathways rather than solely palliative measures. The CNSide platform has demonstrated a remarkable diagnostic sensitivity of 92% and specificity of 95%, markedly improving upon traditional CSF cytology methods. Through this initiative, PLUS Therapeutics aims not only to enhance patient outcomes but also to solidify its leadership role in the realm of cancer diagnostics and therapeutics.

Related news for (PSTV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.